Clinical Trial Update: Second Window Indocyanine Green for All Nervous System Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating second-window indocyanine green for imaging nervous system tumors. Enrollment is by invitation at the Abramson Cancer Center.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nervous System Tumor

Drugs mentioned

• Indocyanine Green (Indocyanine Green)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Nervous System Tumor | Phase 1 | Status: ENROLLING_BY_INVITATION